logo-loader
RNS
Diaceutics PLC

Block Listing Return

RNS Number : 6627X
Diaceutics PLC
07 October 2026
 

Diaceutics PLC

 

BLOCK LISTING RETURN

 

New York, Belfast and London, 7 October 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long term incentive awards.

 

Name of applicant:

Diaceutics PLC

Name of scheme:

UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long-term incentive awards.

Period of return:

From:

7 April 2026

To:

6 October 2026

Balance under scheme from previous return:

1,233,063 Ordinary Shares of £0.002 each

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

N/A

Number of securities issued/allotted under schemes during period:

316,969 Ordinary Shares

 

Balance under scheme not yet issued/allotted at end of period

916,094 Ordinary Shares

Number and class of securities originally listed and the date of admission

1,500,000 Ordinary Shares on 6 October 2023

Total number of securities in issue at the end of the period

85,234,252 Ordinary Shares of £0.002 each

Name of contact:

Nick Roberts

Telephone number of contact:

As below

 

Enquiries: 

Diaceutics PLC   


Nick Roberts, Chief Financial Officer  

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 



Canaccord Genuity Limited (Nomad & Broker) 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees


 

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFIVIFLEIIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read